amp biosimilars AG / Key word(s): Change of Personnel

2015-04-28 / 07:30

amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of the Scientific Board

– Former head of global biopharmaceuticals at Boehringer Ingelheim

– Honorary Senator and professor at the University of Tübingen

– Experience in the development of numerous biosimilars and biopharmaceuticals

Hamburg, 28. April 2015 – amp biosimilars AG (ISIN: DE00A0SMU87), a company specializing in the development of high quality biosimilars, has named Professor Dr. Dr. Rolf G. Werner to head up the Scientific Board, effective immediately. In his new role, Professor Werner will serve as the “Chairman of the Scientific Board”.

Rolf G. Werner is a Professor of Industrial Biotechnology and an Honorary Senator at the Eberhard Karls University Tübingen. He is one of the world’s leading experts in research, development and production of pharmaceutical biotechnologies, with more than 35 years of industry experience in various leadership positions at Boehringer Ingelheim, including head of global biopharmaceuticals. The company’s more than 47,000 employees and revenues of EUR 13.3 billion in 2014 make Boehringer Ingelheim the largest research pharmaceutical company in Germany.

Prof. Werner’s scientific contributions include more than 180 publications, 20 patents and 15 scientific films. His work has been honored with the City of Vienna Prize for his outstanding contributions to science and by the administrative district of Hangzhou, China, where he was named a Hangzhou Qian Jiang Distinguished Expert.

“We are thrilled to have Professor Werner on our team,” says Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. “His vast expertise with every aspect of the development and production of biotechnological materials and pharmaceuticals as well as his international network make him the ideal partner to help identify and commercialize biosimilar blockbusters.”

“It is nothing less than a moral obligation to help find affordable, efficient and safe high quality biosimilars that will give the general global populace the means for improved quality of life, and I am happy to be able to help in this regard,” says Professor Werner, Honorary Senator at the University of Tübingen.

The Scientific Board at amp biosimilars AG is currently composed of three members and supports management with the implementation of its global biosimilar development and commercialization strategy. In addition to its chairman, Prof. Werner, the Scientific Board includes Dr. Holger Ziehr and Dr. Xavier Luria. Dr. Ziehr, head of the Department of Pharmaceutical Biotechnology at the ITEM Fraunhofer Institute, has previously developed numerous biosimilars such as EPO, G-CSF and ß-interferon until the GMP production. Dr. Luria has been the Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), where he coordinated international teams from the 28 EU member states in the regulatory evaluation of medical products.

About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to

MC Services AG
Fabian Lorenz
T +49 211 529252-28


2015-04-28 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

349293  2015-04-28 

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.